SP

Sat Paul Jassal

Active Director Director DIN 07329650
DIN 07329650 First appointment Jun 2016 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 2 active board seats
Total affiliations 2 Since Jun 2016
Shareholding value •••• Premium profile

About Sat Paul Jassal

Data last updated:

Sat Paul Jassal is a Director at Evertogen Life Sciences Limited (since 2021) and Director at Organosyn Life Sciences Private Limited (since 2016). The companies operate in Pharma. The 2 current companies with reported revenue have a combined latest revenue of ₹130 Cr; the largest is Evertogen Life Sciences Limited at ₹89.28 Cr (FY 2024).

DIN 07329650
Primary Designation Director
Industry Pharma
First Appointment 08 Jun 2016
Oldest Company Age 15 yrs
Largest company Evertogen Life Sciences Limited · ₹89.28 Cr (FY 2024)
Combined revenue ₹130 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Evertogen Life Sciences Limited U24232TG2013PLC085349
Director18 Jun 20212013₹89.28 Cr (FY 2024)Active
Director08 Jun 20162011₹40.64 Cr (FY 2025)Active

Directorship timeline

Open interactive timeline →
Organosyn Life Sciences Private Limited
Evertogen Life Sciences Limited
Premium access

Shareholding and investment profile for Sat Paul Jassal

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sat Paul Jassal

Sat Paul Jassal currently holds 2 directorships: Evertogen Life Sciences Limited (Director, since 18 Jun 2021, revenue ₹89.28 Cr (FY 2024)); Organosyn Life Sciences Private Limited (Director, since 08 Jun 2016, revenue ₹40.64 Cr (FY 2025)).

Sat Paul Jassal was first appointed on 08 Jun 2016 as Director at Organosyn Life Sciences Private Limited. The most recent appointment on record is 18 Jun 2021 at Evertogen Life Sciences Limited.

The 2 current companies of Sat Paul Jassal that report revenue have a combined latest revenue of ₹130 Cr: Evertogen Life Sciences Limited ₹89.28 Cr (FY 2024); Organosyn Life Sciences Private Limited ₹40.64 Cr (FY 2025).

The current boards of Sat Paul Jassal's companies include Akhila Thotapally (Evertogen Life Sciences Limited), Manav Jassal (Evertogen Life Sciences Limited), Sherifuddin Sheriff Shaik (Evertogen Life Sciences Limited), Subbarao Kattamuri (Evertogen Life Sciences Limited), Sushma Kattamuri (Evertogen Life Sciences Limited), Vikram Ravindra Mamidipudi (Evertogen Life Sciences Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available